
Oncology MRI
Latest News

Can Gadoxetic Acid-Enhanced MRI Improve Detection of Sub-centimeter HCC Recurrence?

MRI Study Reveals Potentially Severe Impact of NAC Upon Heart and Brain Function in Breast Cancer Patients
Latest Videos

Shorts
More News

Use of an MRI-based deep learning model also led to a greater than 33 percent increase in detecting brain metastases less than or equal to 3 mm, according to newly published research.

The MRI-based Early Recurrence Individualized Score (MERIS) demonstrated an 18 percent higher C-index than the Barcelona Clinic Liver Cancer (BCLC) staging system for predicting early recurrence of hepatocellular carcinoma (HCC) for patients who had resection of solitary HCC tumors.

Catch up on a variety of new FDA clearances and approvals in radiology from the past week.

Catch up on the top radiology content of the past week.

The MEDRAD MRXperion MR Injection System is cleared for use with low-field and high-field MRI platforms, including 7T MRI.

In comparison to LI-RADS version 2018 for MRI assessment, the use of perfluorobutane-enhanced ultrasound incorporating Kupffer-phase findings yielded comparable sensitivity and specificity for detecting hepatocellular carcinoma (HCC) nodules < 20 mm in high-risk patients, according to new research.

Catch up on the most well-viewed video interviews from Diagnostic Imaging in February 2026.

Catch up on the top AI-related news and research in radiology over the past month.

Catch up on a variety of new FDA clearances and approvals in radiology from the past week.

Catch up on the top radiology content of the past week.

MRI Contrast Agent Gadopiclenol Gets Expanded FDA Approval for Children Under Two Years of Age
Previously approved by the FDA in 2022, the macrocyclic gadolinium-based MRI contrast agent gadopiclenol can now be utilized to detect lesions with abnormal vascularity in the central nervous system and other parts of the body for children under the age of two.

New MRI research suggests that adjunctive AI may lead to a significant reduction of unnecessary prostate biopsies.

The FDA clearances include the 1.5T SIGNA Sprint with Freelium MRI platform, the 3T SIGNA Bolt MRI system and the AI-powered SIGNA One, which reportedly enhances MRI workflow efficiencies.

The Mammotome Prima™ MR Dual Vacuum-Assisted Breast Biopsy System reportedly enables larger tissue samples and facilitates more efficiency in procedure setup and cleanup with 75 percent less tubing in comparison to other systems.

In a recent interview, Benjamin Kann, M.D., discussed new research highlighting the capability of an AI foundation model to obtain a variety of diagnostic and prognostic data from brain MRI scans.

Researchers found that PSMA PET/CT offered 18 percent higher accuracy than mpMRI in detecting bilateral intraprostatic disease, according to a new study involving patients with intermediate or high-risk prostate cancer.

Catch up on the top radiology content of the past week.

The Biograph One PET/MRI system may facilitate accelerated scan times, improved visualization and more efficient assessments of theranostic approaches for patients with oncologic and neurological diseases.

Catch up on the most-well viewed radiology content in January 2026.

For young women with breast cancer, peritumoral edema on pre-op breast MRI was associated with over a 3.6-fold higher likelihood for reduced disease-free survival, according to new research.

The use of 5T prostate MRI offered significantly higher signal-to-noise ratio (SNR) than 3T prostate MRI as well as enhanced delineation with T2-weighted and diffusion-weighted imaging, according to newly published comparative research.

Catch up on the top radiology content of the past week.

In a prospective comparison with prior criteria for evaluating hepatocellular carcinoma surveillance, the American Association for the Study of Liver Diseases (AASLD) version 2023 system offered significantly higher sensitivity.

In a seven study meta-analysis with a total of 493 cases involving high-risk breast lesions, researchers found that contrast-enhanced breast MRI did not miss any cases of invasive breast cancer.

Catch up on a variety of new FDA clearances in radiology from the past week.



















